New HeartBeam Patent for 12-Lead Electrocardiogram (ECG) Smartwatch-based Monitor Intended for Detection of Heart Attacks and Complex Cardiac Arrhythmias
November 16 2022 - 8:45AM
Business Wire
Patent Opens Pathway to Disruptive Ischemia and
Arrhythmia Detection Product in Multi-billion Dollar Wearables
Device Market
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector
electrocardiogram (VECG) platform for heart attack detection
anytime, anywhere, announced today that its patent for a 12-lead
electrocardiogram (ECG) smartwatch-based monitor intended for
detection of heart attacks and complex cardiac arrhythmias was
allowed by the United States Patent and Trademark Office. The
innovation builds on HeartBeam’s growing intellectual property
portfolio enabling 12-lead ECG diagnostics outside of a medical
setting.
The global wearables medical device market is estimated to reach
$196B by 2030 and encompasses a wide variety of capabilities,
including diagnostic monitoring such as heart rate and some cardiac
arrhythmias, blood pressure, glucose, respiratory, and sleep
activity, among others. Currently available wearables are not
capable of providing a 12-lead ECG for heart attack detection,
complex arrhythmia monitoring or other cardiac disorders. With
cutting edge 12-lead ECG based on 3D vector ECG technology built
into a smartwatch, HeartBeam’s latest patent further expands on the
Company’s anytime, anywhere capabilities.
“The breakthrough inventions protected by this patent enable our
proprietary 3D ECG technology to be built into a smartwatch,
eliminating the need for a dedicated ECG device while offering a
12-lead ECG capability enabling heart attack and complex arrhythmia
detection,” said HeartBeam CEO and Founder Branislav Vajdic, PhD.
“This patent may prove to be one of the most valuable patents in
our rich and growing patent portfolio and, together with our
12-lead ECG patch patent, I believe, will have a disruptive effect
on these existing multi-billion dollar fast-growing markets,”
concluded Dr. Vajdic.
While HeartBeam is presently focused on the development,
clinical and regulatory activities for the HeartBeam AIMI™ and
AIMIGo™ systems, the Company is committed to continue advancing the
full potential inherent in its cutting edge 12-lead 3D vector ECG
technology as demonstrated in recently issued and allowed patents
with potentially enormous market impacts.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform for
heart attack detection anytime, anywhere. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to determine if symptoms are due to a heart attack,
quickly and easily, so care can be expedited, if required.
HeartBeam has two patented products in development. HeartBeam AIMI™
is software for acute care settings that provides a 3D comparison
of baseline and symptomatic 12-lead ECG to more accurately identify
a heart attack. HeartBeam AIMIGo™ is the first and only credit
card-sized 12-lead output ECG device coupled with a smart phone app
and cloud-based diagnostic software system to facilitate remote
heart attack detection. HeartBeam AIMI and AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221116005578/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact:Capwell Communications
media@capwellcomm.com 949-999-3303
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Aug 2024 to Sep 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Sep 2023 to Sep 2024